BKKT earnings analysis
What we found in BKKT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bakkt delivered a substantial GAAP EPS beat at $1.94 versus $0.07 expected, but the result was heavily supported by a $98.5 million non-cash warrant gain and contrasted with an $11.8 million adjusted EBITDA loss. Revenue fell to $170.1 million from $578 million a year earlier and missed the $340.5 million estimate by approximately 50%. Management maintained its approximately $2.5 billion 2026 transaction-volume and approximately 25,000 December 2026 MAU outlook, but litigation exposure includes a potential $19 million counterclaim and an active appeal.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- GAAP EPS beat aided by non-cash gain
- GAAP EPS was $1.94 versus a $0.07 consensus estimate and improved from a $2.16 loss in Q2 2025. The reported result included a $98.5 million non-cash gain on Transchem warrants, limiting the quality of the earnings beat.
- Revenue fell sharply and missed estimates
- Revenue was $170.1 million, down approximately 70.6% from $578 million in Q2 2025 and approximately 30.3% from $244 million in Q1 2026. Revenue also missed the $340.5 million consensus estimate by approximately 50%.
- Transaction volume outlook maintained
- Transaction volume reached $410.0 million during the quarter, while management maintained its approximately $2.5 billion 2026 transaction-volume expectation.
- Product launches remain targeted for Q4
- Management continues to target approximately 25,000 MAUs in December 2026, with initial co-branded card and Neobank-as-a-Service offerings targeted for Q4 2026.
- No material control weaknesses reported
- The Company stated that its disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, and reported no changes that materially affected internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Underlying losses and earnings quality
- Adjusted EBITDA loss widened to $11.8 million despite reported GAAP EPS of $1.94, indicating that underlying operating performance remained loss-making and the earnings result was materially affected by the $98.5 million non-cash warrant gain.
- Appeal creates litigation exposure
- The Company is seeking approximately $10 million plus attorneys’ fees from Roman, while Roman has asserted counterclaims totaling up to $19 million. Roman filed an appeal on August 6, 2026, and briefing is underway.
- Severe revenue contraction
- Revenue declined approximately 70.6% year over year, from $578 million to $170.1 million, and missed consensus by approximately 50%, highlighting significant top-line volatility.
- Litigation could affect financial condition
- The 10-Q states that an unfavorable litigation resolution could materially affect future business, results of operations, or financial condition, while the maximum stated Roman counterclaims total $19 million.
- No formal risk-factor update
- No material changes were reported to the risk factors from the December 31, 2025 Form 10-K or March 31, 2026 Form 10-Q; however, the pending appeal and claims of up to $19 million remain active legal exposures.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.94
What they said about what is next.
Management maintained expectations for approximately $2.5 billion of 2026 transaction volume and approximately 25,000 December 2026 MAUs. Initial co-branded card and Neobank-as-a-Service offerings remain targeted for Q4 2026, subject to product, partner and regulatory requirements.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Bakkt, Inc. reported a significant decline in Q1 revenue to $243.6 million, down 77.1% from $1.1 billion in Q1 2025, leading to a net loss of $11.7 million compared to a profit of $19.4 million in the prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BKKT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever